The ability to generate functional artificial lymphoid tissue to induce specific immunity at ectopic sites would offer a potential breakthrough for treatment of diseases such as cancer and severe infection using immunotherapy. Artificial lymphoid tissue would also offer an informative tool to further study lymphoid tissue development and function in vivo. Here we review the process of secondary and tertiary lymphoid organization -for which an understanding will be essential for artificial lymphoid tissue synthesis. Using this knowledge, we consider the combination of cell types, soluble factors and scaffold properties that will enable proper accumulation and organization of lymphocytes into tissue grafts. Recent successes with trials for the in vivo induction of artificial lymphoid tissue are also considered.
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. Since both the mature embryonic LTi cells and adult LTi cells are recruited and maintained at the lymphoid tissue anlagen (during embroyogenesis) and at sites of chronic inflammation or infection (in the adult) 18 , they require the capacity to migrate . In the T cell area, FRC networks, and their conduit system, form three-dimensional structures that provide tracks for T cell migration, which is regulated by CCR7. . These reports suggest that diverse stromal cell types exist that constitutively express PTA, and that lymph node stromal cells are involved in the maintenance of tolerance to self-antigens in the periphery. Thus, for the purpose of generating aLT with different immunological functions, including regulatory activity, it will be crucial to clarify the stromal cell heterogeneity in lymphoid organs.
Maintaining a microenvironment for lymphoid tissues formation
The initiation of lymphoid organ formation is triggered by the interaction of . Thus, certain chemokines and cytokines might be important and useful for generating artificial lymphoid tissues.
Scaffolds for artificial lymphoid tissues
Tissue engineering has received much attention in the field of regenerative medicine and is undergoing continuous innovation. and peripheral nervous system 58, 59 . As a matter of course, this is now being applied to lymphoid tissues. Experimentally, to maintain the proper microenvironments at local sites, it will be necessary to attempt transplantation using scaffolds that: 1) contain the appropriate cell populations; 2) contribute to generation of lymphoid organs; 3)
produce soluble factors such as lymphoid chemokines and cytokines that are expressed by stromal cells. A number of synthetic biomaterials are now able to duplicate the three dimensional microenvironments that are provided by natural extracellular matrices, such as fibrillar or non-fibrillar collagen, proteoglycans and matricellular proteins 60, 61 . It has been demonstrated that structurally-engineered macroporous scaffolds, which combine poly ethylene glycal hydrogels with collagen, support T cell and DCs migration 62 . Further advances are being made in this area 60, 61 .
The first in vivo synthesis of artificial lymphoid tissues was achieved using a porous biocompatible collagen matrix, prepared from bovine Achilles tendon (referred to as a collagen sponge) 63 . This matrix has a non-homogeneous pore size ranging from 50-300m. A difficulty in tissue engineering is the achieving the ability to properly modulate or mimick, dynamic tissue microenvironments, for example to achieve appropriate cell recruitment or correct concentration gradients of soluble factors. As a first step toward this goal, biomaterials were recently described that are able to release several soluble factors, not only uniformly, but also gradually with temporal differences 64 . In this study, two growth factors were incorporated together into the same scaffolds by mixing PDGF-encapsulated polymer, lyophilized VEGF and non-treated polymer particles, so that the two growth factors were localized within distinct compartments.
As a result, the scaffold could release the two factors with distinct kinetics and, after transplantation into subcutaneous tissue of Lewis rats, more mature vascular networks were structured than when using the scaffold which contained only a single growth factor 64 . Two other recent studies have also reported that sustained 65 or spatiotemporal 66 delivery of growth factors can lead to formation of a mature vascular system. Thus, in order to efficiently generate artificial organized tissues, the scaffold microenvironment should be carefully constructed to be as close as possible to natural state.
Generating artificial lymphoid tissue in vivo
Generating functional artificial lymphoid tissues might be an important and beneficial . When the aLNs were re-transplanted into SCID mice, and followed by immunization, a robust secondary immune response was induced 63, 70 .
In terms of an in vitro trial to create the human LN environment, it was demonstrated that antigen-specific B cell clusters could be observed in a bioreactor -an ex vivo culture device -containing a porous matrix with antigen-primed DCs . Based on this data, the aAPC might be an effective tool for tumor immunotherapy. The newly established aAPC might be also applicable for generating aLT. To apply artificial lymphoid tissues to human diseases, an in vivo human model would first have to be established, using knowledge from previous mouse experiments. There has been a much progress in the establishment and analysis of humanized mice [78] [79] [80] . NOD/SCID/IL-2 receptor  chain null mice reconstituted with human CD34+ hematopoietic stem cells develop a functional human hematopoietic and immune system. As a result, humanized mice are utilized as a human disease model. They can be experimentally manipulated and can be used to directly study infectious diseases, immunological disorders, as well as cancer therapy in humans [81] [82] [83] [84] . This model system could be a prime candidate for generating human aLT.
Concluding remarks
The idea of generating aLT, especially tissue that is functionally similar to SLO and TLO, is a novel strategy to trigger ectopic adaptive immune responses in vivo, as well as to study the functions of these tissues. Progress in this area might be applied to both locally and systemic treat severe infection, autoimmune diseases, tumors, for example.
From this point of view, trials for construction of human aLT are at a preliminary stage, but could be imperative in the future.
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We thank Peter Burrows for helpful comments on the manuscript. subsets. The presence of these cell types was confirmed by re-transplanting the aLT into SCID mice and followed by immunization, which gave a robust secondary immune response [62, 69] . In these mice antigen-specific high-affinity IgG-producing B Suppression of recurrent tumor growth
